Busulfan, melphalan and carfilzomib high‐dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma

Documenti analoghi

• Outcomes of frail patients undergoing high‐dose chemotherapy and autologous stem cell transplantation for multiple myeloma
  di: Stephanie Yohay, et al.
  Pubblicazione: (2024)
• Induction prior to autologous haematopoietic cell transplantation in multiple myeloma
  di: Mohamad Mohty, et al.
  Pubblicazione: (2024)
• A rare complication during autologous stem cell transplantation in multiple myeloma
  di: Valeria Tomarchio, et al.
  Pubblicazione: (2025)
• Early M‐protein immune reconstitution after autologous haematopoietic stem cell transplantation is a good prognostic marker for patients with high‐risk cytogenetic multiple myeloma
  di: Huihui Zhu, et al.
  Pubblicazione: (2024)
• Comparable peri‐transplant mortality and incidence of febrile neutropenia after high‐dose melphalan and autologous stem cell transplantation in patients with plasma cell dyscrasias treated as outpatient versus inpatient
  di: Ana Maria Avila Rodriguez, et al.
  Pubblicazione: (2025)